U.S. Supreme Court Declines to Hear Bausch Health’s Patent Appeal, Impacting IBS Drug Market

In a recent decision, the U.S. Supreme Court declined to review the appeal from a Bausch Health unit aiming to overturn a ruling by the Federal Circuit. The earlier decision invalidated certain patents associated with a high-profile drug for treating irritable bowel syndrome with diarrhea. This drug, developed by Salix Pharmaceuticals, a division of Bausch Health, has been a significant player in the market for managing this specific type of irritable bowel syndrome. As the Supreme Court decision stands, the ruling from the Federal Circuit remains in effect, which poses potential implications for the pharmaceutical industry regarding patent protection. Read more about this case.